Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday. The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use. The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said. In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease. |
Katharine McPhee bares her taut tummy in a black sports bra and leggings as she does PilatesSyrian President Bashar Assad visits Iran to express condolences over death of RaisiBiden to make his first state visit to France after attending DBritain's Got Talent's Sydnie Christmas receives a kiss after semiKieran McKenna signs 4Toni Colette is all smiles as she enjoys a picnic with Andy Garcia in ItalyLarry Lamb reveals the lie he told Ruth Jones when she asked him to do the Gavin And Stacey reunionFamilies reclaim the remains of 15 recently identified Greek soldiers killed in Cyprus in 1974Jordanian youths excel in Chinese proficiency competitionOhio attorney general must stop blocking proposed ban on police immunity, judges say